echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Genentech reaches approximately US$600 million in cooperation with oral bacteria to deliver therapeutic drugs

    Genentech reaches approximately US$600 million in cooperation with oral bacteria to deliver therapeutic drugs

    • Last Update: 2022-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Novome Biotechnologies announced that it has reached a multi-year research cooperation and licensing agreement with Genentech, a subsidiary of Roche


    Inflammatory bowel diseases include Crohn's disease and ulcerative colitis


    Novome developed the GEMMs technology platform through engineering design of Lactococcus lactis, which is common in food


    ▲The mechanism of the GEMMs platform (picture source: Novome's official website)

    According to the terms of the agreement, Novome will be responsible for the research activities of engineered bacteria until the start of supporting preclinical research authorized by the IND


    Reference materials:

    [1] Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.